TABLE 1.
Clinical variables and skin AGEs levels in present participants
| Patients with | Fisher's exact test | Post hoc test | ||||||
|---|---|---|---|---|---|---|---|---|
| SZ | MDD | MND | HC | p value | χ 2 | p value | Z | |
| n = 27 | n = 26 | n = 10 | n = 24 | |||||
| Sex, M/F | 8/19 | 13/13 | 5/5 | 3/21 | .021 | 9.354 | .005 (MDD vs. HC) | −2.811 |
| Kruskal–Wallis test | ||||||||
| Age, mean ± SD (years) | 53.7 ± 8.9 | 53.1 ± 7.4 | 61.3 ± 8.3 | 53.0 ± 6.5 | .067 | 7.157 | NA | |
| BMI, mean ± SD (kg/m2) | 23.0 ± 3.9 | 22.0 ± 1.9 | 22.2 ± 3.0 | 21.2 ± 2.1 | .252 | 4.086 | NA | |
| Clinical symptoms | 34.2 ± 14.7 (BPRS) | 7.3 ± 6.8 (HAM‐D) | 23.9 ± 5.8 (MMSE) | NA | NA | |||
| ANCOVA * | ||||||||
| p value | F | |||||||
| Skin AGE levels, mean ± SD (A.U.) | 230.2 ± 40.5 | 238.5 ± 46.9 | 257.0 ± 39.9 | 234.6 ± 45.1 | .91 | 0.181 | NA | |
Note: Patients with schizophrenia (SZ, n = 27), major depressive disorder (MDD, n = 26), major neurocognitive disorder (MND, n = 10), and healthy controls (HCs, n = 24).
Abbreviations: AGEs, advanced glycation end products; BMI, body mass index; NA, not applicable.
a
Detailed statistical values for ANCOVA are provided in the Section 3 of the text. p values with statistical significance are in bold.